Lisanti Capital Growth’s Standard BioTools LAB Stock Holding History

Lisanti Capital Growth’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-50,995	Closed	-$2.15M	–	95
2015 Q1	$2.15M	Buy	+50,995	New	+$2.02M	1.22%	31
2014 Q2	–	Sell	-11,085	Closed	-$489K	–	104
2014 Q1	$489K	Buy	+11,085	New	+$488K	0.21%	92

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Lisanti Capital Growth's LAB Position: Q2 2015 in Review

Lisanti Capital Growth sold out of Standard BioTools (LAB) in Q2 2015, closing a stake of 50,995 shares — an estimated $2.15M sold.

Lisanti Capital Growth first reported a position in LAB in Q1 2014 and held it in 2 quarters. The position peaked at $2.15M in Q1 2015. 107 funds tracked by Wall St. Rank hold LAB as of Q2 2015.

Lisanti Capital Growth reported no remaining Standard BioTools position as of Q2 2015 after selling out during the quarter.
Lisanti Capital Growth sold 50,995 Standard BioTools shares in Q2 2015, an estimated $2.15M.
Lisanti Capital Growth first reported a position in Standard BioTools in Q1 2014 and held it in 2 quarters.
Lisanti Capital Growth's Standard BioTools position peaked at $2.15M in Q1 2015.
107 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2015.

Based on Lisanti Capital Growth's 13F filing for Q2 2015, filed 24 Jul 2015.